Nicolas Tilmans, Anagenex CEO

Seek­ing to 'close the loop' in drug dis­cov­ery with ma­chine learn­ing, Catalio-backed biotech emerges from se­mi-stealth

Two years af­ter se­cur­ing seed fund­ing and re­main­ing in a state of “se­mi-stealth,” a San Fran­cis­co biotech keen on com­bin­ing evo­lu­tion and small mol­e­cule dis­cov­ery …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.